Citadel Advisors’s Sharps Compliance Corp SMED Stock Holding History

Citadel Advisors’s Portfolio SMED Stock Details SMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,800	Closed	-$37K	–	14213
2022 Q2	$37K	Sell	12,800 -700	-5%	-$2.92K	﹤0.01%	12121
2022 Q1	$80K	Buy	+13,500	New	+$84.8K	﹤0.01%	12482
2021 Q3	–	Sell	-33,500	Closed	-$345K	–	15125
2021 Q2	$345K	Sell	33,500 -12,200	-27%	-$170K	﹤0.01%	10928
2021 Q1	$657K	Buy	45,700 +9,200	+25%	+$118K	﹤0.01%	9094
2020 Q4	$345K	Buy	36,500 +25,300	+226%	+$193K	﹤0.01%	8825
2020 Q3	$70K	Buy	+11,200	New	+$81.5K	﹤0.01%	9467
2015 Q4	–	Sell	-5,300	Closed	-$46K	–	9374
2015 Q3	$46K	Sell	5,300 -4,200	-44%	-$30.4K	﹤0.01%	7647
2015 Q2	$66K	Buy	+9,500	New	+$59.5K	﹤0.01%	7460

Citadel Advisors's SMED Position: Q3 2022 in Review

Citadel Advisors sold out of Sharps Compliance Corp (SMED) in Q3 2022, closing a stake of 62,818 shares — an estimated $184K sold.

Citadel Advisors first reported a position in SMED in Q1 2014 and held it in 11 quarters. The position peaked at $1.31M in Q2 2021. 0 funds tracked by Wall St. Rank hold SMED as of Q3 2022.

Citadel Advisors reported no remaining Sharps Compliance Corp position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 62,818 Sharps Compliance Corp shares in Q3 2022, an estimated $184K.
Citadel Advisors first reported a position in Sharps Compliance Corp in Q1 2014 and held it in 11 quarters.
Citadel Advisors's Sharps Compliance Corp position peaked at $1.31M in Q2 2021.
0 funds tracked by Wall St. Rank held Sharps Compliance Corp as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.